Posts in category Most Popular


Analyst Colin Rusch Sets Neutral Expectations on Tesla Inc (TSLA) Model 3 and Tonight’s Semi Debut

Oppenheimer’s Colin Rusch angles for “intrigue,” but recognizes challenges still face TSLA.

Read more

MannKind Corporation (MNKD) CEO Told This Analyst Afrezza’s Revenue Would Build, Not Fall – Q3 Turnout Disappoints

Jason Kolbert recently downgraded MNKD on cash flow concerns; after this Q3 print, looks like he was right.

Read more

This Analyst Doesn’t Think Snap Inc (SNAP) Stock Worth The Cheap Price

Snap misses across the board for Q3 earnings, stock gets whacked; Brian Wieser reiterates a Sell.

Read more

Valeant Pharmaceuticals Intl Inc’s (VRX) Situation Remains Dire: Irina Rivkind Koffler

Is Valeant on track to overcome financial troubles? Mizuho’s Irina Rivkind Koffler remains unconvinced.

Read more

Analyst Jay Olson Sets Sights on TherapeuticsMD Inc (TXMD) Dyspareunia Asset TX-004HR Following Encouraging Regulatory Strides

Oppenheimer predicts TXMD to launch TX-004HR by mid-2018 with a January approval from the FDA.

Read more

Analyst Rick Schafer Bets on NVIDIA Corporation (NVDA) Ahead of FQ3 Showcase

Rick Schafer: Data center and gaming momentum will bode well for NVDA’s anticipated quarterly outclass.

Read more

TherapeuticsMD Inc (TXMD) Shares Fire Up to the Roof Following Positive FDA Resolution; William Tanner Cheers

TX-004 is on the path to FDA approval; Cantor’s William Tanner Sees 450% Upside.

Read more

Oclaro Inc (OCLR) Gets A Price Target Wind-Down From a Bull; Here’s Why

Dave Kang: OCLR shares wait on China to strengthen in the back half of F2018 and cloud recovery in F4Q .

Read more

GoPro Inc (GPRO) Is Impressing Andrew Uerkwitz with Execution and a Potential Path to Sustainable Growth

Oppenheimer: The capture market is looking better and GPRO just made a strong comeback with 3Q results.

Read more

ACADIA Pharmaceuticals Inc. (ACAD) Announces Presentation of Data Showing Greater Benefit in Patients with Severe Psychosis

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced the presentation of data from the Phase II -019 Study …

Read more